Merck Announces FDA 510(k) Clearance of Partner Genea Biomedx#s Fertility Benchtop Incubator Geri(TM)

Food and Healthcare Press Releases Wednesday December 6, 2017 09:49
DARMSTADT, Germany--6 Dec--PRNewswire/InfoQuest
Not intended for U.S. based media
  • Expanded Fertility Technology portfolio highlights Merck's commitment to improve fertility treatment outcomes for patients
  • U.S. commercial availability expected in first half of 2018

Merck, a leading science and technology company, today announced the FDA 510(K) clearance of the benchtop embryo incubator Geri(TM). This innovative technology, designed to improve processes in fertility laboratories, will be commercially available to IVF clinics in the U.S. in the first half of 2018.

(Photo: http://mma.prnewswire.com/media/615557/Merck_Geri.jpg )

With the FDA 510(K) clearance of Geri(TM), an incubator for continuous embryo monitoring, Merck will help to advance assisted reproductive treatment (ART) technologies by offering new, relevant solutions to patients and their healthcare professionals.

"Geri(TM) is one of the flagship products of our fertility technologies portfolio and has been successfully used in clinics across Australia, Europe and Asia for the last two years," said Rehan Verjee, Chief Marketing and Strategy Officer at Merck's biopharma business. "Offering Geri(TM) in the U.S. will allow us to further our aspiration of becoming an integrated fertility treatment partner, continuously aiming to improve treatment outcomes."

An incubator is critical for embryo development while it is being cultured outside of the uterus. Getting as close as possible to in-vivo incubation conditions is essential to ensure the most favorable environment for embryonic development, given that exposure to non-optimal conditions outside of an incubator may affect the viability and quality of embryos.[1],[2],[3],[4] Geri(TM) was designed by embryologists who know the lab processes and what optimizes successful embryo growth. Geri(TM) has six individual chambers, each independently controlled, facilitating the care of the embryos of six patients at the same time. It is equipped with high-definition cameras to take a picture of the embryos every 5 minutes and provide continuous imaging so the supervising embryologist can observe embryos as they develop without removing them from their optimum environment. This minimizes lid openings and potential disruptions that can cause stress to embryos.

"Genea Biomedx is an IVF medical device company uniquely positioned within a clinical fertility business allowing it direct access to world leading IVF laboratories. This enabled us to develop Geri(TM) in collaboration with the embryologists that use it day in, day out," said Dr. Tammie Roy, General Manager at Genea Biomedx. "We are looking forward to working with EMD Serono to bring our innovative technology to clinics across the U.S."

With the exception of Australia, Geri(TM) is distributed by Merck through its Fertility Technologies unit, in accordance with a global distribution agreement executed with Genea Biomedx in May 2015. Additional products in the Fertility Technologies portfolio of EMD Serono, the biopharmaceutical business of Merck in the U.S. and Canada, include Gems(TM), culture media allowing for high-quality embryo cultivation that was granted an FDA 510(k) clearance this summer, and Gidget(TM) a hand-held witnessing system that provides electronic witnessing, visual lab workflow management and support for traceability and audit reporting.

References
1. Zhang et al. Reproductive BioMedicine Online (2010) 20, 510-515
2. Swain, J.E., Decisions for the IVF laboratory: comparative analysis of embryo culture incubators, Reproductive BioMedicine Online (2014), doi: http://dx.doi.org/10.1016/j.rbmo.2014.01.004
3. Bontekoe S, Cochrane Database of Systematic Reviews 2012, Issue 7
4. Kirkegaard, K.et al. Fertility and sterility 99.3 (2013): 738-744
About Geri(TM)

Geri(TM) is a benchtop incubator with individually controlled incubation chambers per patient to minimize disruptive events to the early-stage embryo and blastocyst. It also incorporates a camera to real-time monitor the developing embryos. Geri(TM) was developed by Genea Biomedx, a company that creates and manufactures practical, accessible and precise fertility technologies that help standardize and automate fertility treatment.

About Gems(TM)
Gems(TM) is the latest generation of Genea Biomedx's culture media suite for high-quality embryo cultivation.
About Gidget(TM)

Gidget(TM) is a hand-held witnessing system for the IVF laboratory that allows the embryologist to focus on the science by helping to ensure that gametes and embryos are matched correctly. Gidget(TM) provides electronic witnessing, visual lab workflow management and support for traceability and audit reporting.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Your Contact: Dr. Raphaela Farrenkopf, +49 6151 72-2274
(Logo: http://photos.prnewswire.com/prnh/20160913/406891LOGO )
Source: Merck

Latest Press Release

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Data Presented at 2nd Healthy Lung Summit 2018 to Demonstrate Impact of AstraZeneca#s Healthy Lung Partnership Programme

Deepening commitment to drive improvements for patients with respiratory disease across Asia, AstraZeneca with Business Sweden, The Swedish Trade & Invest Council in Taiwan, hosts the second Healthy Lung Summit, ahead of the 2018 Asia Pacific Society...

Encore Medical Education Will Publish the Best of SABCS(R) News From 2018 San Antonio Breast Cancer Symposium (SABCS)

Encore Medical Education will publish the Best of SABCS(R) News highlighting the key findings presented at the 41st San Antonio Breast Cancer Symposium (SABCS(R)), to be held on December 4-8, 2018 in San Antonio, Texas, USA. The Best of SABCS(R) News...

Related Topics